

PHILIPS

Turbo-Power

Laser atherectomy
catheter



Safe.
Effective.
Proven.

Use **photoablation** to vaporize the ISR challenge

In-stent restenosis (ISR)

115,000⁺/year (U.S.)¹⁻⁶

Repeated narrowing of the arteries after a stent has been placed. "FemPop ISR" occurs in the femoropopliteal artery.

Chance of recurring⁷



Many treatments, no clear path...



Mechanical atherectomy danger of stent interaction^{7,8}



PTA (Angioplasty) high recurrence rate⁹⁻¹¹



Bypass surgery risk and cost^{12,13}

...until now.

The Philips Turbo-Power laser atherectomy catheter




Maximal luminal gain

Proven clinically superior*

Indicated for ISR



*used with PTA vs. PTA alone



ACUTE MI

2

08/22/2007 11:07:00
1110

VL1: PROXIMAL POST STENT (PAUSED)

Pullback: 1630 Frames

Draw

Dots

End Case

Archive

Toolbar

A proven solution to the ISR challenge:


the Turbo-Power laser atherectomy catheter

FDA cleared indication for ISR

Is your current treatment of choice indicated for ISR?

	Indicated	Contraindicated	Not Indicated
Turbo-Power	✓		
Directional		⊘	
Orbital		⊘	
Rotational			⊘

Remote automatic rotation offers precise directional control





Photoablates restenotic tissue with the only technology backed by level 1 clinical evidence¹⁴

New design features eccentric vaporizing technology for maximal luminal gain

Treats at the tip creating a pilot channel and debulking the lesion in one step

Maximal luminal gain

Success begins and ends with luminal gain. Eccentric fiber bundle, and precise directional control, provide up to **27% greater luminal gain*** when compared to Turbo-Elite 2.0.




*when comparing 7F Turbo-Power to 2.0 Turbo-Elite. >10% luminal gain when comparing 6F Turbo-Power to 2.0 Turbo-Elite.¹⁹

Clinical superiority

Level 1 clinical data proves it. The Excite* ISR prospective randomized controlled trial included challenging real-world cases with the **longest lesions ever studied**.¹⁴

Safer¹⁴

More effective¹⁴



* Excite ISR studied the safety and efficacy of Turbo-Tandem plus PTA and PTA alone. Turbo-Power is substantially equivalent to Turbo-Tandem.
** After treatment.

■ Turbo-Tandem + PTA
■ PTA alone

	Turbo-Power	SilverHawk TurboHawk HawkOne	DiamondBack 360	Jetstream
Proven superior in safety and efficacy	✓			
Maximal luminal gain ¹⁴⁻¹⁸	✓	✓		
ISR indication	✓	Contraindicated	Contraindicated	Not indicated
Treats at the tip	✓			✓
Precise directional control	✓	✓		
Treats mixed morphologies	✓	✓		✓
Level 1 clinical data	✓			

Specifications

Catheter diameter	2.3 mm	2.0 mm
Model number	423-050	420-050
Vessel diameter	≥3.5 mm	≥3.0 mm
Max guidewire compatibility	0.018"	0.018"
Sheath compatibility	7F	6F
Max tip outer diameter	0.091"	0.080"
Max shaft outer diameter	0.091"	0.081"
Working length	120 cm	150 cm
Fluence (mJ/mm ²)	30-60	30-60
Repetition rate (Hz)	25-80	25-80

- Schillinger et al (2007). Sustained benefit at 2 years of primary femoropopliteal stenting compared with balloon angioplasty with optional stenting. *Circulation*; 115: 2745-9.
- Saxon et al (2013). Heparin bonded, expanded polytetrafluoroethylene lined stent graft in the treatment of femoropopliteal artery disease. *JVIR*; 24(2).
- Geraghty et al (2013). Three year results of the VIBRANT trial of VIABAHN endoprosthesis versus bare nitinol stent implantation for complex superficial femoral artery occlusive disease. *JVS*; 58(2): 386-95.
- Dake, M (2012). Zilver PTX Paclitaxel-Eluting Stents for Femoropopliteal Disease: 24-month results of the randomized study, LINC, Leipzig, Germany.
- Ansel (2012). Japanese Association of Cardiovascular Intervention and Therapeutics (CVIT), Niigata, Japan.
- Spectranetics Data on File, 2014.
- Tosaka et al (2012). Classification and Clinical Impact of Restenosis After Femoropopliteal Stenting. *Interventional Cardiology*; 59: 16-23.
- Minar, E (2010). Recent advances in peripheral in-stent restenosis. *J Cardiovasc Surg*; 51: 539-41.
- Dippel et al (2013). Atherectomy for femoropopliteal In-Stent Restenosis: A review of the current data on the role of atherectomy devices in debulking these difficult lesions. *Endovascular Today*, 59-62.
- SilverHawk Instructions for Use, <http://www.ev3.net/peripheral/us/plaque-excision/silverhawk-plaque-excision-system-with-proprietary-mec-technology.htm>, June 2014.
- Diamondback Instructions for Use, http://www.csi360.com/uploads/rte/file/pdf/90109-00_J.pdf, June 2014.
- Nehler et al (2003). Functional outcomes and quality of life in peripheral arterial disease: current status. *Vasc Med*; 8: 115.
- Bradbury et al (2002). Bypass or Angioplasty for Severe Limb Ischemia? A Delphi Consensus Study. *Eur J Vasc Endovasc Surg*; 24: 411-416.
- Dippel et al. Randomized Controlled Study of Excimer Laser Atherectomy for Treatment of Femoropopliteal In-stent Restenosis: Initial EXCITE ISR Results (2015). *JACC* 8(1): 92-101.
- McKinsey J, Zellar T, Rocha-Singh K, et al. Lower Extremity Revascularization Using Directional Atherectomy: 12-Month Prospective Results of the DEFINITIVE LE Study, *JACC Cardiovasc Interv* 7 (2014) pp. 923-933.
- Maehara A, et al. JETSTREAM Atherectomy System can remove superficial calcium in severely calcified peripheral arteries. Abstract Poster, ISET Jan 2013.
- Babaev A, et al. Tissue Removal Assessment with Ultrasound of the SFA and Popliteal Study (TRUTH): Orbital Atherectomy Acute Date and Intravascular Ultrasound Analysis. *JACC Vol 64/11/Suppl B*, TCT-131.
- Maximal luminal gain defined as 50% or greater stenosis reduction.
- Spectranetics Benchmark Study, unpublished data available upon request. *Coll Cardio*. 2004;43:1959-1963.

